Ophthalmic composition containing n-acetyl-cysteine for the treatment of dry-eye syndrome
CA 2454918 A1 · Owner: Farmigea S.P.A. · Inventors: Burgalassi, Susi; Boldrini, Enrico; Giannaccini, Boris
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
An ophthalmic pharmaceutical composition containing acetyl cysteine as the active ingredient having a mucolitic action suitable for administration in , eyedrops where N-acetyl-cysteine is neutralised with base DEAE-dextrane in order to reach pH levels preferably between 6.0 and 7.5 and having a , physiologically acceptable osmolarity less than 320 mOsm/kg. The presence of a neutralising agent for N-acetyl-cysteine that does not negatively affect the composition osmolarity allows the formulation to be isotonic or even hypotonic, thus avoiding the irritative and potentially damaging effects of previous ophthalmic products containing N-acetyl-cysteine
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 22, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 22, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 22, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.